[go: up one dir, main page]

SE510666C2 - Nya Kristallmodifikationer - Google Patents

Nya Kristallmodifikationer

Info

Publication number
SE510666C2
SE510666C2 SE9604793A SE9604793A SE510666C2 SE 510666 C2 SE510666 C2 SE 510666C2 SE 9604793 A SE9604793 A SE 9604793A SE 9604793 A SE9604793 A SE 9604793A SE 510666 C2 SE510666 C2 SE 510666C2
Authority
SE
Sweden
Prior art keywords
omeprazole
neutral
solution
solvent
water
Prior art date
Application number
SE9604793A
Other languages
English (en)
Swedish (sv)
Other versions
SE9604793L (sv
SE9604793D0 (sv
Inventor
Martin Bohlin
Karol Horvath
Sverker Von Unge
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE510666(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9604793A priority Critical patent/SE510666C2/sv
Publication of SE9604793D0 publication Critical patent/SE9604793D0/xx
Priority to TW086118449A priority patent/TW538039B/zh
Priority to ZA9711046A priority patent/ZA9711046B/xx
Priority to YUP-281/99A priority patent/RS49685B/sr
Priority to NZ336024A priority patent/NZ336024A/en
Priority to TR1999/01410T priority patent/TR199901410T2/xx
Priority to RU99116303/04A priority patent/RU2184734C2/ru
Priority to PCT/SE1997/002125 priority patent/WO1998028294A1/fr
Priority to US09/000,154 priority patent/US6162816A/en
Priority to JP52868598A priority patent/JP4402174B2/ja
Priority to SK765-99A priority patent/SK285151B6/sk
Priority to EEP199900259A priority patent/EE03923B1/xx
Priority to CZ19992202A priority patent/CZ294784B6/cs
Priority to SI9730528T priority patent/SI0946547T1/xx
Priority to ARP970105920A priority patent/AR010361A1/es
Priority to CA002274076A priority patent/CA2274076C/fr
Priority to PT97951367T priority patent/PT946547E/pt
Priority to EP97951367A priority patent/EP0946547B1/fr
Priority to IDW990483A priority patent/ID21850A/id
Priority to BR9714059-7A priority patent/BR9714059A/pt
Priority to HK00101986.4A priority patent/HK1022909B/en
Priority to DK97951367T priority patent/DK0946547T3/da
Priority to IL13045097A priority patent/IL130450A0/xx
Priority to HU0001547A priority patent/HU227589B1/hu
Priority to AT97951367T priority patent/ATE236898T1/de
Priority to CN97180849A priority patent/CN1109684C/zh
Priority to KR1019997005574A priority patent/KR20000069595A/ko
Priority to PL97334297A priority patent/PL190377B1/pl
Priority to UA99073869A priority patent/UA55436C2/uk
Priority to ES97951367T priority patent/ES2194231T3/es
Priority to DE69720774T priority patent/DE69720774T2/de
Priority to AU55026/98A priority patent/AU730129B2/en
Priority to MYPI97006176A priority patent/MY117032A/en
Priority to EG136097A priority patent/EG24414A/xx
Priority to SA97180739A priority patent/SA97180739B1/ar
Publication of SE9604793L publication Critical patent/SE9604793L/xx
Priority to IS5070A priority patent/IS1981B/is
Publication of SE510666C2 publication Critical patent/SE510666C2/sv
Priority to NO19993068A priority patent/NO317191B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE9604793A 1996-12-20 1996-12-20 Nya Kristallmodifikationer SE510666C2 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer
TW086118449A TW538039B (en) 1996-12-20 1997-12-08 Neutral S-omeprazole in a form or b form, process for preparing the same, and pharmaceutical composition comprising the same
ZA9711046A ZA9711046B (en) 1996-12-20 1997-12-09 A novel compound form.
DE69720774T DE69720774T2 (de) 1996-12-20 1997-12-16 S-omeprazol in festform
AU55026/98A AU730129B2 (en) 1996-12-20 1997-12-16 A novel compound form
EP97951367A EP0946547B1 (fr) 1996-12-20 1997-12-16 Nouvelle forme de compose
HK00101986.4A HK1022909B (en) 1996-12-20 1997-12-16 A novel compound form
TR1999/01410T TR199901410T2 (xx) 1996-12-20 1997-12-16 Yeni bir bile�im bi�imi.
RU99116303/04A RU2184734C2 (ru) 1996-12-20 1997-12-16 S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния
PCT/SE1997/002125 WO1998028294A1 (fr) 1996-12-20 1997-12-16 Nouvelle forme de compose
US09/000,154 US6162816A (en) 1996-12-20 1997-12-16 Crystalline form of the S-enantiomer of omeprazole
JP52868598A JP4402174B2 (ja) 1996-12-20 1997-12-16 新規な化合物形態
SK765-99A SK285151B6 (sk) 1996-12-20 1997-12-16 Neutrálna forma S-enantioméru omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie
EEP199900259A EE03923B1 (et) 1996-12-20 1997-12-16 S-omeprasool neutraalsel kujul, selle valmistamise protsess ja seda sisaldavad ravimsegud
CZ19992202A CZ294784B6 (cs) 1996-12-20 1997-12-16 Nová forma S-omeprazolu
SI9730528T SI0946547T1 (en) 1996-12-20 1997-12-16 A novel compound form
ARP970105920A AR010361A1 (es) 1996-12-20 1997-12-16 "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
CA002274076A CA2274076C (fr) 1996-12-20 1997-12-16 Nouvelle forme de compose
PT97951367T PT946547E (pt) 1996-12-20 1997-12-16 Nova forma de composto
YUP-281/99A RS49685B (sr) 1996-12-20 1997-12-16 Novi oblik jedinjenja
IDW990483A ID21850A (id) 1996-12-20 1997-12-16 Formula senyawa baru
BR9714059-7A BR9714059A (pt) 1996-12-20 1997-12-16 S-omeprazol em uma forma neutra, processo para preparar o mesmo, uso deste, composição farmacêutica, e, processo para tratar uma condição relacionada com ácido gástrico.
NZ336024A NZ336024A (en) 1996-12-20 1997-12-16 Neutral crystalline S-omeprazole
DK97951367T DK0946547T3 (da) 1996-12-20 1997-12-16 Hidtil ukendt forbindelsesform
IL13045097A IL130450A0 (en) 1996-12-20 1997-12-16 A novel compound form
HU0001547A HU227589B1 (en) 1996-12-20 1997-12-16 Crystal form of (s)-omeprazole
AT97951367T ATE236898T1 (de) 1996-12-20 1997-12-16 S-omeprazol in festform
CN97180849A CN1109684C (zh) 1996-12-20 1997-12-16 新的化合物形态
KR1019997005574A KR20000069595A (ko) 1996-12-20 1997-12-16 신규한 형태의 화합물
PL97334297A PL190377B1 (pl) 1996-12-20 1997-12-16 S-Omeprazol w postaci obojętnej, sposób wytwarzania S-omeprazolu, środek farmaceutyczny i zastosowanie S-omeprazolu
UA99073869A UA55436C2 (uk) 1996-12-20 1997-12-16 Нова форма s-омепразолу, спосіб його одержання, фармацевтична композиція та використання у виробництві лікувального засобу
ES97951367T ES2194231T3 (es) 1996-12-20 1997-12-16 Una nueva forma de compuesto.
MYPI97006176A MY117032A (en) 1996-12-20 1997-12-19 A novel compound form.
EG136097A EG24414A (en) 1996-12-20 1997-12-20 A novel compound form
SA97180739A SA97180739B1 (ar) 1996-12-20 1997-12-27 الشكل البللوري للمتشاكل S - enantiomer للأومبرازول omeprazole
IS5070A IS1981B (is) 1996-12-20 1999-06-07 Nýtt form S-handhverfu ómeprasóls og lyfjablöndursem innihalda það
NO19993068A NO317191B1 (no) 1996-12-20 1999-06-21 S-omeprazol i noytral form, fremgangsmate for fremstilling derav, farmasoytisk preparat inneholdende en slik form, og anvendelse derav

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer

Publications (3)

Publication Number Publication Date
SE9604793D0 SE9604793D0 (sv) 1996-12-20
SE9604793L SE9604793L (sv) 1998-06-21
SE510666C2 true SE510666C2 (sv) 1999-06-14

Family

ID=20405146

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer

Country Status (36)

Country Link
US (1) US6162816A (fr)
EP (1) EP0946547B1 (fr)
JP (1) JP4402174B2 (fr)
KR (1) KR20000069595A (fr)
CN (1) CN1109684C (fr)
AR (1) AR010361A1 (fr)
AT (1) ATE236898T1 (fr)
AU (1) AU730129B2 (fr)
BR (1) BR9714059A (fr)
CA (1) CA2274076C (fr)
CZ (1) CZ294784B6 (fr)
DE (1) DE69720774T2 (fr)
DK (1) DK0946547T3 (fr)
EE (1) EE03923B1 (fr)
EG (1) EG24414A (fr)
ES (1) ES2194231T3 (fr)
HU (1) HU227589B1 (fr)
ID (1) ID21850A (fr)
IL (1) IL130450A0 (fr)
IS (1) IS1981B (fr)
MY (1) MY117032A (fr)
NO (1) NO317191B1 (fr)
NZ (1) NZ336024A (fr)
PL (1) PL190377B1 (fr)
PT (1) PT946547E (fr)
RS (1) RS49685B (fr)
RU (1) RU2184734C2 (fr)
SA (1) SA97180739B1 (fr)
SE (1) SE510666C2 (fr)
SI (1) SI0946547T1 (fr)
SK (1) SK285151B6 (fr)
TR (1) TR199901410T2 (fr)
TW (1) TW538039B (fr)
UA (1) UA55436C2 (fr)
WO (1) WO1998028294A1 (fr)
ZA (1) ZA9711046B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
JP2000344739A (ja) * 1999-06-01 2000-12-12 Sumitomo Chem Co Ltd Ｎ−保護−アゼチジン−２−カルボン酸の製造方法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ES2521690T3 (es) 2000-05-15 2014-11-13 Takeda Pharmaceutical Company Limited Procedimiento para producir un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridil]metil]sulfinil]-bencimidazol
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
WO2002012225A1 (fr) 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
EP2260837A1 (fr) 2001-06-01 2010-12-15 Pozen, Inc. Compositions pharmaceutiques pour l'administration coordonnée d'AINS
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1515963B1 (fr) * 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
CA2491118A1 (fr) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
CA2501424A1 (fr) * 2002-08-30 2004-03-11 Dr. Reddy's Laboratories Limited Hydrates amorphes d'esomeprazole magnesium et leur procede de preparation
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
CN1728997A (zh) * 2002-10-22 2006-02-01 兰贝克赛实验室有限公司 (es)奥美拉唑的无定形盐
WO2004046134A2 (fr) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Composes d'esomeprazole cristallins et procede permettant de preparer ces composes
BRPI0407906A (pt) * 2003-02-28 2006-02-14 Ranbaxy Lab Ltd polimorfos de s-omeprazol
EP1607395B1 (fr) 2003-03-24 2011-05-04 Eisai R&D Management Co., Ltd. Procédé de préparation de sel de sodium de rabeprazole amorphe
WO2004099181A1 (fr) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Sel de baryum d'un derive de benzimidazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20090298884A1 (en) * 2005-05-06 2009-12-03 Glenmark Generics Ltd. Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
EP1907375B1 (fr) * 2005-06-08 2013-07-24 LEK Pharmaceuticals d.d. Solvate cristallin de sodium d'omeprazole
EP1891043A1 (fr) 2005-06-15 2008-02-27 Hetero Drugs Limited Ésoméprazole hydraté amorphe
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
WO2007054951A1 (fr) * 2005-11-14 2007-05-18 Hetero Drugs Limited Procédé d'obtention d’ésoméprazole amorphe
US8124779B2 (en) * 2005-12-05 2012-02-28 Astrazeneca Ab Process for the preparation of esomeprazole non-salt form
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
KR101289215B1 (ko) 2005-12-28 2013-07-29 유니온 퀴미코 파르마세우티카, 에스.에이. 오메프라졸의 (에스)-엔안티오머의 제조 방법
EP2000468A1 (fr) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Sels d'ésoméprazole et procédés pour leur préparation
EP2195309A4 (fr) 2007-10-08 2013-04-24 Hetero Drugs Ltd Polymorphes de sels de l'ésoméprazole
MX2010009641A (es) 2008-03-10 2010-09-22 Takeda Pharmaceutical Cristal de compuestos de bencimidazol.
EP2143722A1 (fr) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
CN102209529A (zh) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
SG181535A1 (en) 2009-12-08 2012-07-30 Codexis Inc Synthesis of prazole compounds
WO2012078800A2 (fr) 2010-12-08 2012-06-14 Codexis, Inc. Biocatalyseurs et procédés de synthèse de l'armodafinil
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
CN107043367A (zh) * 2017-05-26 2017-08-15 重庆莱美隆宇药业有限公司 一种中性s‑奥美拉唑的干燥工艺
WO2024075017A1 (fr) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition de calcification de valve aortique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
ATE206044T1 (de) * 1994-07-08 2001-10-15 Astrazeneca Ab Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)

Also Published As

Publication number Publication date
BR9714059A (pt) 2000-05-09
IS5070A (is) 1999-06-07
ATE236898T1 (de) 2003-04-15
PT946547E (pt) 2003-07-31
RS49685B (sr) 2007-11-15
IL130450A0 (en) 2000-06-01
CZ220299A3 (cs) 2000-02-16
EE03923B1 (et) 2002-12-16
NO993068L (no) 1999-06-21
YU28199A (sh) 2002-03-18
KR20000069595A (ko) 2000-11-25
HUP0001547A3 (en) 2002-06-28
NZ336024A (en) 2001-02-23
HK1022909A1 (en) 2000-08-25
PL190377B1 (pl) 2005-12-30
TW538039B (en) 2003-06-21
SE9604793L (sv) 1998-06-21
WO1998028294A1 (fr) 1998-07-02
DE69720774D1 (de) 2003-05-15
IS1981B (is) 2005-01-14
AU5502698A (en) 1998-07-17
CN1241183A (zh) 2000-01-12
SE9604793D0 (sv) 1996-12-20
MY117032A (en) 2004-04-30
EG24414A (en) 2009-05-25
RU2184734C2 (ru) 2002-07-10
CZ294784B6 (cs) 2005-03-16
NO993068D0 (no) 1999-06-21
HU0001547D0 (fr) 2002-05-29
HUP0001547A2 (hu) 2002-05-29
ID21850A (id) 1999-08-05
HU227589B1 (en) 2011-09-28
ZA9711046B (en) 1998-06-22
EP0946547B1 (fr) 2003-04-09
AR010361A1 (es) 2000-06-07
SK76599A3 (en) 1999-12-10
UA55436C2 (uk) 2003-04-15
SA97180739B1 (ar) 2006-05-20
ES2194231T3 (es) 2003-11-16
EE9900259A (et) 2000-02-15
DK0946547T3 (da) 2003-06-30
TR199901410T2 (xx) 1999-08-23
SI0946547T1 (en) 2003-10-31
CN1109684C (zh) 2003-05-28
DE69720774T2 (de) 2004-02-05
AU730129B2 (en) 2001-02-22
PL334297A1 (en) 2000-02-14
CA2274076C (fr) 2008-09-30
SK285151B6 (sk) 2006-07-07
CA2274076A1 (fr) 1998-07-02
US6162816A (en) 2000-12-19
NO317191B1 (no) 2004-09-13
JP2001507025A (ja) 2001-05-29
EP0946547A1 (fr) 1999-10-06
JP4402174B2 (ja) 2010-01-20

Similar Documents

Publication Publication Date Title
SE510666C2 (sv) Nya Kristallmodifikationer
SE510643C2 (sv) Termodynamiskt stabil omeprazol natrium form B
MXPA04009384A (es) Polimorfos de lansoprazol y proceso para la preparacion de los mismos.
JP2012246316A (ja) エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
JP2000511909A (ja) 修飾された形態を有するｒ（―）―ｎ―（４，４―ジ（３―メチルチエン―２―イル）ブタ―３―エニル）―ニペコチン酸・塩酸塩
JP3345814B2 (ja) ２６―（ジアルキルアミノアルキルスルホニル）プリスチナマイシンｉｉｂから誘導される新規な塩類
KR100274736B1 (ko) 6-엔-(엘-에이엘에이-엘-에이엘에이)-트로바플록사신 전구약물의 폴리모프
CN109776532B (zh) 具有抗菌活性的取代2-酰胺基-1,10-菲罗啉
HK1022909B (en) A novel compound form
HRP980251A2 (en) New form of a compound
MXPA99005661A (en) A novel compound form
JPH01160972A (ja) １，２，４−トリアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤
JPH0959260A (ja) チアミンジスルフィド類及びこれを有効成分とする医薬
KR20070023757A (ko) 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정변형의 제조를 위한 신규한 방법
WO1998020877A1 (fr) Disulfides de thiamine, et medicaments contenant ces substances en tant qu'ingredients actifs
WO1989002430A1 (fr) Nouveau compose de choline, son procede de preparation et nouveaux medicaments le contenant